Wolverine (BPC-157 + TB-500)
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
The “Wolverine stack” is the most popular recovery combination in the peptide world, and the logic behind it is clean: take the two best-known repair peptides — one that works locally and fast, one that works systemically — and run them together so you cover repair from both angles in a single shot. It’s named after the comic character who heals from anything, and it’s exactly what it sounds like: BPC-157 and TB-500, 5 mg of each, co-formulated in one vial.
This blend’s evidence base is its two components’ evidence — so the BPC-157 and TB-500 articles are the deep dives, and this page is the stack rationale, the combined protocol, and the honest status of “the two together.” The framing worth keeping is the same as always: this is a recovery accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, patience. On that foundation, it’s a convenient, well-reasoned, popular tool.
What does it do in my body?
The rationale is genuinely sound on paper, which is why this pairing caught on with practitioners (one practitioner references originating the protocol; Bakri confirms “Wolverine = BPC-157 + TB-500” is the established street taxonomy). The two peptides hit different, complementary repair levers:
- BPC-157 — the local repair signal. Drives angiogenesis (new blood vessels) via VEGF/VEGFR2 and activates the FAK–paxillin pathway so collagen-laying fibroblasts crawl into an injury and rebuild it. Acts fast and often near the injection site [PMID 18594781, 25415472].
- TB-500 — the systemic coordinator. Sequesters actin to mobilize cells over distance, dials inflammation down via NF-κB/TGF-β suppression, and reduces fibrosis/scarring. Longer-acting and body-wide [PMID 22074294, 36580759].
Local plumbing and FAK-paxillin healing (BPC-157) plus systemic cell-migration and anti-inflammation (TB-500): the migrating cells TB-500 mobilizes need the blood supply and matrix BPC-157 helps build, so the mechanisms genuinely dovetail. That complementary logic is why this is the default recovery stack.
The honest framing: the complementary-mechanism case is a strong rationale — it’s how the combination was reasoned into existence — and it’s well grounded in each peptide’s separate biology. It hasn’t been measured as a combination (see below), so treat the “synergy” as a well-motivated hypothesis backed by heavy real-world use, not a quantified finding.
How can it help me?
- Best fit: The popular all-in-one recovery stack — local + systemic repair in a single shot
- Where the science stands: Each component has its own preclinical + early-human record — BPC-157 now has published human pilots incl. intra-articular knee pain [PMID 34324435] (see component pages); no dedicated study of the two co-administered
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The blend’s tolerability is each component’s profile run together, and both are well-tolerated.
- Injection-site itching / irritation — most common; rotate sites, clean technique.
- Mood / dopaminergic effects (from the BPC-157 component) — occasional anxiety or flattened mood; lower the dose or pause if noticed.
- Mild headache or lethargy (from the TB-500 component) — occasional, transient.
- Cancer caution — the shared angiogenesis/growth-pathway concern; suspected or active malignancy is a sensible reason to consult an oncologist first. Pregnancy commonly listed as a contraindication.
As with the single agents, the largest real-world variable is product quality — whether the vial actually contains both peptides at the stated dose and identity. A fixed-ratio blend makes a third-party COA especially valuable, because it verifies both components at once.
Regulatory status: Not FDA-approved. Both components are banned by WADA and on the U.S. DoD prohibited list; BPC-157’s acetate form was removed from FDA compounding Category 2 in April 2026 but is not yet on Category 1. The combination itself has no separate regulatory recognition. Sold legally as a research chemical, “not for human consumption.”
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution (objective math, this 5mg/5mg vial). Add 2 mL bacteriostatic water → 2.5 mg/mL of EACH peptide (2,500 mcg/mL each). A 500-mcg-each dose = 0.2 mL = 20 units on a U-100 insulin syringe, delivering 500 mcg BPC-157 + 500 mcg TB-500 in one shot. Add water slowly down the vial wall, swirl gently (never shake), refrigerate reconstituted.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Community-standard protocol (mirrors the single-agent conventions):
- Dose: ~500 mcg of each per dose (20 units from this vial).
- Frequency: once daily is the common all-in-one cadence; some run AM/PM early in a cycle. Because TB-500 is longer-acting, daily-to-every-other-day works once the cycle is established.
- Cycle: a focused 4–8 week repair block, 8 weeks on / off, run to the recovery goal.
One practical limitation worth knowing: because both peptides come out of the same vial in a fixed 1:1 ratio, you can’t titrate them independently. If you want to run, say, more BPC-157 locally near an injury and less TB-500 systemically, separate vials give you that control — the blend trades flexibility for convenience and a single injection. The all-in-one is the simplest path; separate BPC-157 + TB-500 vials are the flexible path. Many users who want the denaturing question off the table also prefer separate vials dosed from two syringes.
What should I avoid combining — and what's synergistic?
Stacking further. Adding GHK-Cu turns the Wolverine pairing into GLOW (collagen/skin layer); adding KPV makes it KLOW (immune/anti-inflammatory layer). It also pairs naturally alongside a Retatrutide fat-loss phase for joint and recovery support (Williams and Jones both endorse BPC/TB alongside Reta).
How can I buy this?
Alyve sells the blend as BPC-157 + TB-500 (5mg/5mg) at $69.99, in stock. The lot (BPTB32) carries a third-party Certificate of Analysis from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity): 99.23% purity — the highest of Alyve’s structural-repair SKUs, with both peptides identity-confirmed.
That dual-identity confirmation is the strongest reason to buy a blend like this from a verified vendor rather than the gray market. A two-peptide vial is harder to eyeball for content and identity than a single agent, and independent testing has found roughly 1 in 4 research peptides underdosed, mislabeled, or contaminated (often with leftover TFA salt, often with no COA). A large 2026 gray-market purity analysis (Mendias et al., preprint — 6,441 samples across 14 compounds, both BPC-157 and TB-500 included) puts hard data under exactly this risk for both halves of the blend. A 99.23%-pure, LC-MS-confirmed report that names both BPC-157 and TB-500 is exactly the trust signal a blend needs — it tells you the convenience of one vial didn’t cost you certainty about what’s inside.
Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. A recovery cycle on a daily protocol moves through product, so a 3-bottle order is how committed users buy the Wolverine stack.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
| Class | Two-peptide recovery blend: BPC-157 (5 mg) + TB-500 (5 mg) in one vial |
| Mechanism (one line) | Pairs BPC-157’s local angiogenesis + FAK–paxillin repair with TB-500’s systemic actin-driven cell migration and anti-inflammatory action — repair from two complementary angles |
| Route / frequency | Subcutaneous; both peptides dose together from the fixed-ratio vial |
| Evidence base | Each component has its own preclinical + early-human record — BPC-157 now has published human pilots incl. intra-articular knee pain [PMID 34324435] (see component pages); no dedicated study of the two co-administered |
| Safety record | Both components well-tolerated individually; mild injection-site reactions most common |
| Regulatory status | Not FDA-approved; both components WADA-banned |
| Alyve product | BPC-157 + TB-500 5mg/5mg, $69.99 · COA 99.23% (lot BPTB32) — the highest-purity structural SKU · OHM-15 |
| Best-fit user | The popular all-in-one recovery stack — local + systemic repair in a single shot |
What it is
The “Wolverine stack” is the most popular recovery combination in the peptide world, and the logic behind it is clean: take the two best-known repair peptides — one that works locally and fast, one that works systemically — and run them together so you cover repair from both angles in a single shot. It’s named after the comic character who heals from anything, and it’s exactly what it sounds like: BPC-157 and TB-500, 5 mg of each, co-formulated in one vial.
This blend’s evidence base is its two components’ evidence — so the BPC-157 and TB-500 articles are the deep dives, and this page is the stack rationale, the combined protocol, and the honest status of “the two together.” The framing worth keeping is the same as always: this is a recovery accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, patience. On that foundation, it’s a convenient, well-reasoned, popular tool.
How it works
The rationale is genuinely sound on paper, which is why this pairing caught on with practitioners (one practitioner references originating the protocol; Bakri confirms “Wolverine = BPC-157 + TB-500” is the established street taxonomy). The two peptides hit different, complementary repair levers:
- BPC-157 — the local repair signal. Drives angiogenesis (new blood vessels) via VEGF/VEGFR2 and activates the FAK–paxillin pathway so collagen-laying fibroblasts crawl into an injury and rebuild it. Acts fast and often near the injection site [PMID 18594781, 25415472].
- TB-500 — the systemic coordinator. Sequesters actin to mobilize cells over distance, dials inflammation down via NF-κB/TGF-β suppression, and reduces fibrosis/scarring. Longer-acting and body-wide [PMID 22074294, 36580759].
Local plumbing and FAK-paxillin healing (BPC-157) plus systemic cell-migration and anti-inflammation (TB-500): the migrating cells TB-500 mobilizes need the blood supply and matrix BPC-157 helps build, so the mechanisms genuinely dovetail. That complementary logic is why this is the default recovery stack.
The honest framing: the complementary-mechanism case is a strong rationale — it’s how the combination was reasoned into existence — and it’s well grounded in each peptide’s separate biology. It hasn’t been measured as a combination (see below), so treat the “synergy” as a well-motivated hypothesis backed by heavy real-world use, not a quantified finding.
What the research shows
The combination itself: a PubMed search returns no published study of BPC-157 + TB-500 co-administered — human, animal, or in-vitro — as of mid-2026. There are no combination PK or interaction studies. So the blend’s evidence is assessed component-by-component, and the “stack” is a practitioner/real-world construct supported by extensive anecdotal use rather than a trial of the pair. That’s the straight status — stated once, plainly.
Each component, though, brings a real body of evidence (full detail on the component pages):
- BPC-157 — a deep, consistent preclinical record across tendon (Achilles transection, [PMID 18594781]), ligament (MCL, [PMID 20225319]), gut (ulcer protection, [PMID 7904712]), and vascular models, with independent reviews [PMID 30915550, 40756949] confirming “consistently positive and prompt healing effects.” Early human use now includes published small pilots: intra-articular knee-pain [PMID 34324435] — directly relevant to this stack’s joint/recovery use — plus an interstitial-cystitis pilot [PMID 39325560], an IV-infusion safety pilot [PMID 40131143], and placebo-controlled Phase 1/2 ulcerative-colitis enema trials. Safety record clean.
- TB-500 / Thymosin Beta-4 — coherent preclinical biology (actin/migration, angiogenesis, anti-fibrosis [PMID 22074294, 36580759, 27450736]) plus human data for clinical-grade Tβ4: an rhTB4 STEMI RCT (overall non-significant, positive early-dosing subgroup, [PMID 41229390]), and Phase 2 eye-drop and dermal-wound trials [PMID 30063853, 27450738].
The angiogenesis / cancer note, shown honestly: both peptides act partly through angiogenesis and growth-related pathways, so the theoretical tumor-promotion concern that applies to each applies to the blend. The counter-context from the actual data is the same as on the component pages: BPC-157 shows no carcinogenic signal in animal work and in a melanoma model decreased tumor VEGF, while TB-500/Tβ4’s anti-fibrotic and anti-inflammatory arms cut against a simple “growth = cancer” read. The practical takeaway is unchanged: anyone with active or suspected malignancy should treat this as a reason to talk to an oncologist first; for everyone else it remains a theoretical, mechanism-level caution, not documented harm.
Where experts land: one practitioner treats the combined repair effect as obvious and reliable from his clinical use and originated the protocol; Bakri treats the pairing as plausible and widely used but notes (as for any peptide combo) the open question of whether co-mixing two peptides in one vial risks denaturing. Both endorse the stack as a real-world tool; they differ on how much certainty to attach to “synergy” beyond each component’s own action.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Reconstitution (objective math, this 5mg/5mg vial). Add 2 mL bacteriostatic water → 2.5 mg/mL of EACH peptide (2,500 mcg/mL each). A 500-mcg-each dose = 0.2 mL = 20 units on a U-100 insulin syringe, delivering 500 mcg BPC-157 + 500 mcg TB-500 in one shot. Add water slowly down the vial wall, swirl gently (never shake), refrigerate reconstituted.
Community-standard protocol (mirrors the single-agent conventions):
- Dose: ~500 mcg of each per dose (20 units from this vial).
- Frequency: once daily is the common all-in-one cadence; some run AM/PM early in a cycle. Because TB-500 is longer-acting, daily-to-every-other-day works once the cycle is established.
- Cycle: a focused 4–8 week repair block, 8 weeks on / off, run to the recovery goal.
One practical limitation worth knowing: because both peptides come out of the same vial in a fixed 1:1 ratio, you can’t titrate them independently. If you want to run, say, more BPC-157 locally near an injury and less TB-500 systemically, separate vials give you that control — the blend trades flexibility for convenience and a single injection. The all-in-one is the simplest path; separate BPC-157 + TB-500 vials are the flexible path. Many users who want the denaturing question off the table also prefer separate vials dosed from two syringes.
Stacking further. Adding GHK-Cu turns the Wolverine pairing into GLOW (collagen/skin layer); adding KPV makes it KLOW (immune/anti-inflammatory layer). It also pairs naturally alongside a Retatrutide fat-loss phase for joint and recovery support (Williams and Jones both endorse BPC/TB alongside Reta).
Side effects & management
The blend’s tolerability is each component’s profile run together, and both are well-tolerated.
- Injection-site itching / irritation — most common; rotate sites, clean technique.
- Mood / dopaminergic effects (from the BPC-157 component) — occasional anxiety or flattened mood; lower the dose or pause if noticed.
- Mild headache or lethargy (from the TB-500 component) — occasional, transient.
- Cancer caution — the shared angiogenesis/growth-pathway concern; suspected or active malignancy is a sensible reason to consult an oncologist first. Pregnancy commonly listed as a contraindication.
As with the single agents, the largest real-world variable is product quality — whether the vial actually contains both peptides at the stated dose and identity. A fixed-ratio blend makes a third-party COA especially valuable, because it verifies both components at once.
Regulatory status
Not FDA-approved. Both components are banned by WADA and on the U.S. DoD prohibited list; BPC-157’s acetate form was removed from FDA compounding Category 2 in April 2026 but is not yet on Category 1. The combination itself has no separate regulatory recognition. Sold legally as a research chemical, “not for human consumption.”
The Alyve product
Alyve sells the blend as BPC-157 + TB-500 (5mg/5mg) at $69.99, in stock. The lot (BPTB32) carries a third-party Certificate of Analysis from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity): 99.23% purity — the highest of Alyve’s structural-repair SKUs, with both peptides identity-confirmed.
That dual-identity confirmation is the strongest reason to buy a blend like this from a verified vendor rather than the gray market. A two-peptide vial is harder to eyeball for content and identity than a single agent, and independent testing has found roughly 1 in 4 research peptides underdosed, mislabeled, or contaminated (often with leftover TFA salt, often with no COA). A large 2026 gray-market purity analysis (Mendias et al., preprint — 6,441 samples across 14 compounds, both BPC-157 and TB-500 included) puts hard data under exactly this risk for both halves of the blend. A 99.23%-pure, LC-MS-confirmed report that names both BPC-157 and TB-500 is exactly the trust signal a blend needs — it tells you the convenience of one vial didn’t cost you certainty about what’s inside.
Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. A recovery cycle on a daily protocol moves through product, so a 3-bottle order is how committed users buy the Wolverine stack.
Sources
No combination studies exist; sources are the component literatures — see BPC-157 and TB-500 for full lists.
- (PMIDs 18594781, 20225319, 7904712, 25415472, 30915550, 40756949; human pilots 34324435, 39325560, 40131143) and (PMIDs 41229390, 22074294, 36580759, 27450736, 30063853, 27450738).
- confirms 0 combination records.
- the three new BPC-157 human pilots and the Mendias 2026 gray-market purity preprint (both components tested).
- (lot BPTB32, 99.23%).
- Video digests: one practitioner BPC-157 (2026-06-02), Huberman/Bakri (2026-06-01, Wolverine/GLOW sections).
Related: BPC-157 · TB-500 · GLOW · KLOW · Retatrutide.